CSL Faces Vifor Competition: Jefferies Downgrades Stock
CSL's Vifor Faces Intensifying Competition
Jefferies has downgraded CSL to 'hold' from 'buy', citing difficulties in the growth of the pharmaceutical company's Vifor business in the short term. Analyst David Stanton highlights price competition from generic drug Venofer and negative currency swings as key challenges.
Forecast: 15% Decline in Vifor Revenue
Jefferies expects a 15% decline in Vifor iron revenue for FY27 and a 300 basis-point contraction in CSL Vifor EBIT margin. These headwinds add to pressures on CSL's Behring division, which accounts for the majority of revenue.
The price target was slashed by 45% to A$108.00 per share. CSL shares closed at A$97.59 on Thursday.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…